Intellia Therapeutics (NASDAQ:NTLA) Shares Up 6.8%

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) traded up 6.8% on Monday . The stock traded as high as $22.22 and last traded at $22.18. 566,817 shares were traded during mid-day trading, a decline of 62% from the average session volume of 1,476,637 shares. The stock had previously closed at $20.76.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NTLA. Canaccord Genuity Group lifted their price objective on Intellia Therapeutics from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Friday, February 23rd. Wedbush reaffirmed a "neutral" rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Wolfe Research assumed coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. Finally, The Goldman Sachs Group downgraded Intellia Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $67.00.

Intellia Therapeutics Stock Performance

The business has a 50 day simple moving average of $26.39 and a 200-day simple moving average of $27.47. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -4.06 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. The business had revenue of ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. During the same period in the prior year, the firm posted ($1.40) EPS. As a group, research analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares in the company, valued at $2,691,027.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NTLA. Blue Trust Inc. bought a new stake in Intellia Therapeutics in the 4th quarter valued at about $26,000. Signaturefd LLC lifted its position in shares of Intellia Therapeutics by 89.3% during the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company's stock worth $49,000 after acquiring an additional 751 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Intellia Therapeutics by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,263 shares of the company's stock valued at $72,000 after purchasing an additional 1,108 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in Intellia Therapeutics by 35.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company's stock worth $93,000 after purchasing an additional 793 shares in the last quarter. Finally, Spire Wealth Management grew its holdings in Intellia Therapeutics by 3,789.0% during the 4th quarter. Spire Wealth Management now owns 3,889 shares of the company's stock valued at $119,000 after buying an additional 3,789 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.